[Prøvning af enhed, der ikke er godkendt eller godkendt af U.S. FDA]
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The NOVOCLEAR™ Device is a radiofrequency-based hand-held device intended to treat chronic rhinitis by delivering pulsed field energy to soft tissues in the nasal airway, including the posterior nasal nerve distribution. The NOVOCLEAR™ Device is used with the AVENTIX™ PFX System. The AVENTIX™ PFX System is a radiofrequency-based electrosurgical system designed to deliver non-thermal pulsed field energy to the targeted tissue.
This is a non-significant risk, prospective, multi-center, single arm study to evaluate the safety, effectiveness and tolerability of the NOVOCLEAR™ Device used with the AVENTIX™ PFX System.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: ClinicalAdmin
- Telefonnummer: (510) 912-2589
- E-mail: clinical@aventixmed.com
Studiesteder
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80923
- Rekruttering
- Colorado ENT and Allergy
-
Ledende efterforsker:
- Bryan Davis, MD
-
Kontakt:
- Monica Davis
- Telefonnummer: (719) 867-7804
-
-
Mississippi
-
Ocean Springs, Mississippi, Forenede Stater, 39564
- Rekruttering
- Bay Area ENT
-
Kontakt:
- Raymond Weiss, MD
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78256
- Rekruttering
- Atkins Expert Sinus Care
-
Kontakt:
- James Atkins, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- The subject is 18 to 85 years of age.
- The subject has had symptoms of chronic rhinitis for greater than 6 months with insufficient response to nasal steroids.
- The subject has an rTNSS total score of ≥ 6.
- The subject has had moderate to severe symptoms of rhinorrhea and/or nasal congestion (rTNSS rating of 2 or 3 for rhinorrhea and 1, 2, or 3 for congestion)
- The subject is able and willing to provide written informed consent and comply with the protocol requirements.
Exclusion Criteria:
- The subject has clinically significant anatomic obstructions on either side that limit access to the posterior nose, including severe septal deviation, nasal polyps, and sinonasal tumor
- The subject has a septal perforation
- The subject has had prior sinus or nasal surgery on either side that significantly alters the anatomy of the posterior nose.
- The subject had had previous surgery of the PNN for chronic rhinitis.
- The subject has had prior head or neck irradiation
- The subject has an active or chronic nasal or sinus infection
- The subject has active coagulation disorder, or the patient is receiving anticoagulants
- The subject has a history of dry eye or dry nose symptoms
- Patient has rhinitis medicamentosa
- The subject has ocular allergic symptoms
- The subject has a history of nose bleeds
- The subject has electrically sensitive implants (e.g. cochlear implants, pacemakers, defibrillators)
- The subject is pregnant or lactating
- The subject is participating in another clinical research study
- The subject has an allergy or intolerance to anesthetic agent
- Any physical condition that, in the Investigator's opinion, would prevent adequate study participation or pose an increased risk
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: NOVOCLEAR™ Device Treatment Group
Subjects treated with pulsed field energy applied to soft tissues in the nasal airway, including the posterior nasal nerve distribution.
|
Pulsed field energy applied to soft tissues in the nasal airway, including the posterior nasal nerve distribution.
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean change in Reflective Total Nasal Symptom Score (rTNSS) at 90 days compared to baseline.
Tidsramme: 90 days
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
90 days
|
|
Proportion of subjects with device and/or procedure-related serious adverse events through 90 days
Tidsramme: 90 days
|
Characterization of the type and frequency of study device and/or study procedure-related adverse events reported during or following the study procedure through 90 days follow-up.
|
90 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Mean change in rTNSS at 7 days compared to baseline
Tidsramme: 7 days
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
7 days
|
|
Mean change in rTNSS at 14 days compared to baseline
Tidsramme: 14 days
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
14 days
|
|
Mean change in rTNSS at 30 days compared to baseline
Tidsramme: 30 days
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
30 days
|
|
Mean change in rTNSS at 6 months compared to baseline
Tidsramme: 6 months
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
6 months
|
|
Mean change in rTNSS at 1 year compared to baseline
Tidsramme: 1 year
|
The rTNSS is the sum of 4 individual subject-assessed symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing, each evaluated using a scale of 0=None, 1=Mild, 2=Moderate, or 3=Severe.
Total scores range from 0 to 12.
A higher score indicates increased symptom severity.
|
1 year
|
|
Mean procedure tolerability using a Visual Analogue Scale (VAS) at post-procedure
Tidsramme: Post-procedure
|
Immediately after the study procedure, subjects will be asked to rate the pain they experienced in their nasal cavity(ies) during the procedure using a 100 mm visual analogue scale with 0 mm representing no pain and 100 mm representing worst pain imaginable.
|
Post-procedure
|
|
Subject satisfaction at 90 days
Tidsramme: 90 days
|
Subjects will be asked two questions regarding their satisfaction with the study procedure. The first question asks; How satisfied with your procedure are you?; with the following five response options: very satisfied, satisfied, neutral, unsatisfied, or very unsatisfied. The second question asks; How likely are you to refer a friend for this procedure?; with the following five response options: very likely, likely, neutral, unlikely, or very unlikely. |
90 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Raymond Weiss, MD, Bay Area ENT
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- A2024-01
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .